News
Janssen/MeiraGTx showcase nine-month data for sight loss gene therapy
MeiraGTx and Janssen Pharmaceuticals have announced nine-month data from the ongoing phase I/II trial of their investigational gene therapy for X-linked retinitis pigmentosa (XLRP).